A new clinical trial is set to explore the potential of remote ischemic conditioning as a novel therapeutic approach for individuals with cognitive impairment stemming from cerebral small vessel disease. Sponsored by Jiangsu Province Nanjing Brain Hospital, researchers aim to investigate the efficacy, safety, and performance of the IPC-906 device through a carefully controlled study. As of January 11, 2026, recruitment for participants has yet to begin.
In this article:
- What is this clinical trial about?
- What is the study design?
- Who should care about this trial?
- FAQ
- What are the implications?
- Important disclaimer
What is this clinical trial about?
The trial focuses on individuals affected by cerebral small vessel disease (CSVD), a condition that often results in cognitive impairment. Remote ischemic conditioning involves using a medical device to induce brief, controlled periods of restricted blood flow, with the aim of triggering protective effects in the brain. Researchers will use the IPC-906 device for this purpose, comparing its outcomes to a sham (inactive) procedure.
What is the study design?
Primary objectives
The trial is designed to evaluate the clinical benefits of remote ischemic conditioning in improving cognitive function in individuals diagnosed with CSVD. Key metrics will include changes in cognitive performance, overall brain health, and associated safety data.
Devices involved
Two different interventions will be tested:
- Device: Remote ischemic conditioning using the IPC-906 device
- Device: Sham remote ischemic conditioning using the IPC-906 device
Both devices will appear identical, ensuring participants are blinded regarding whether they are receiving the active treatment or the sham control.
Recruitment status
As of the announced date, the study has not yet started recruiting participants. This status highlights that regulatory, logistical, or preparatory processes are still underway.
Who should care about this trial?
This information is particularly significant for research teams, regulatory professionals, and clinicians specializing in CSVD or neurodegenerative diseases. For manufacturers and stakeholders in medical device innovation, this clinical trial offers insights into deploying novel technologies in real-world settings.
FAQ
- Who sponsors the study?
The trial is sponsored by Jiangsu Province Nanjing Brain Hospital. - What condition is targeted?
The study targets cognitive impairment caused by cerebral small vessel disease. - Which device is tested?
The IPC-906 device is under evaluation. - When does recruitment begin?
Recruitment has not yet started as of January 11, 2026.
What are the implications?
This trial serves as a critical step forward in assessing whether remote ischemic conditioning can be a viable medical device-based approach to manage cognitive impairment in CSVD. As researchers continue their work, stakeholders in the healthcare and medical device sectors should monitor its developments closely.
Important disclaimer
This article is intended for informational purposes only and should not be used as legal or professional medical advice.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07317557?term=medical+device